These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36420703)

  • 1. Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups.
    Gerritsen JKW; Zwarthoed RH; Kilgallon JL; Nawabi NL; Versyck G; Jessurun CAC; Pruijn KP; Fisher FL; Larivière E; Solie L; Mekary RA; Satoer DD; Schouten JW; Bos EM; Kloet A; Tewarie RN; Smith TR; Dirven CMF; De Vleeschouwer S; Vincent AJPE; Broekman MLD
    Neuro Oncol; 2023 May; 25(5):958-972. PubMed ID: 36420703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study.
    Gerritsen JKW; Zwarthoed RH; Kilgallon JL; Nawabi NL; Jessurun CAC; Versyck G; Pruijn KP; Fisher FL; Larivière E; Solie L; Mekary RA; Satoer DD; Schouten JW; Bos EM; Kloet A; Nandoe Tewarie R; Smith TR; Dirven CMF; De Vleeschouwer S; Broekman MLD; Vincent AJPE
    Lancet Oncol; 2022 Jun; 23(6):802-817. PubMed ID: 35569489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical supramaximal resection for newly diagnosed left-sided eloquent glioblastoma: safety and improved survival over gross-total resection.
    Di L; Shah AH; Mahavadi A; Eichberg DG; Reddy R; Sanjurjo AD; Morell AA; Lu VM; Ampie L; Luther EM; Komotar RJ; Ivan ME
    J Neurosurg; 2023 Jan; 138(1):62-69. PubMed ID: 35623362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
    Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
    J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL
    Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
    Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
    Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series.
    Navarria P; Pessina F; Clerici E; Rossini Z; Franceschini D; D'Agostino G; Franzese C; Comito T; Loi M; Simonelli M; Lorenzi E; Persico P; Politi LS; Grimaldi M; Bello L; Santoro A; Fornari M; Servadei F; Scorsetti M
    J Neurosurg; 2021 Jul; 135(1):64-77. PubMed ID: 32886916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery.
    Shah AS; Sylvester PT; Yahanda AT; Vellimana AK; Dunn GP; Evans J; Rich KM; Dowling JL; Leuthardt EC; Dacey RG; Kim AH; Grubb RL; Zipfel GJ; Oswood M; Jensen RL; Sutherland GR; Cahill DP; Abram SR; Honeycutt J; Shah M; Tao Y; Chicoine MR
    J Neurosurg; 2021 Aug; 135(2):505-514. PubMed ID: 33035996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
    Bloch O; Han SJ; Cha S; Sun MZ; Aghi MK; McDermott MW; Berger MS; Parsa AT
    J Neurosurg; 2012 Dec; 117(6):1032-8. PubMed ID: 23039151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.
    Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Clerici E; Rossi M; Scorsetti M; Bello L
    J Neurooncol; 2017 Oct; 135(1):129-139. PubMed ID: 28689368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.
    Coburger J; Hagel V; Wirtz CR; König R
    PLoS One; 2015; 10(6):e0131872. PubMed ID: 26115409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma.
    Ahmadipour Y; Kaur M; Pierscianek D; Gembruch O; Oppong MD; Mueller O; Jabbarli R; Glas M; Sure U; El Hindy N
    J Neurol Surg A Cent Eur Neurosurg; 2019 Jul; 80(4):262-268. PubMed ID: 30965373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.
    Orringer D; Lau D; Khatri S; Zamora-Berridi GJ; Zhang K; Wu C; Chaudhary N; Sagher O
    J Neurosurg; 2012 Nov; 117(5):851-9. PubMed ID: 22978537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of reproducibility in MRI quantitative volumetric assessment and its role in the prediction of overall survival and progression-free survival in glioblastoma.
    Blomstergren A; Rydelius A; Abul-Kasim K; Lätt J; Sundgren PC; Bengzon J
    Acta Radiol; 2019 Apr; 60(4):516-525. PubMed ID: 29966430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.